Syncope medical therapy

Syncope Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Syncope from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X ray
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Syncope medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Syncope medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Syncope medical therapy
CDC on Syncope medical therapy
Syncope medical therapy in the news
Blogs on Syncope medical therapy
Directions to Hospitals Treating Syncope
Risk calculators and risk factors for Syncope medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical therapy is the mainstay of the treatment.

Medical Therapy

Medical therapy is the mainstay of the treatment.

Recommendations for treatment of cardiac syncope

Bradyarrhythmia (Class I, Level of Evidence C):

❑ Implantation of dual chamber permanent pacemaker in chronic bifascicular block but without documented high grade AV block

Supraventricular tachycardia(Class I, Level of Evidence C) :

❑ Treatment of the arrhythmia based on guideline directed medical theray Uncommon causes of syncope especially in younger patients In the syncope related to SVT , vasovagal syncope or ventricular arrhythmia should be investigated In the syncope related to rapid atrail fibrillation without preexcitation, vasovagal syncope and sinus node dysfunction in the presence of long pause should be considered

Ventriculat arrhythmia : (Class I, Level of Evidence C)

❑ Treatment of tachyarrhythmia based on the guideline and underlying cardiac causes of ventricular arrhythmia ❑ Making decision for ICD implantation related to the recurrence of tachyarrhythmia In ventricular tachycardia with the rate>200 min, the incidence of syncope and near syncope is 65%

Ischemic and non ischemic cardiomyopathy:(Class I, Level of Evidence C)

❑ Treatment of underlying causes of cardiomyopathy ❑ ICD implantation in the presence of ventricular arrhythmia during electrophysiological study

Valvular heart disease : (Class I, Level of Evidence C)

❑Aortic valve replacement should be considered in patients with severe AS and exersional syncope In the syncope related to severe aortic stenosis, the mechanism of syncope is low cardiac out put state

Hypertrophic cardiomyopathy (Class I , Level of Evidence C):

❑ Inadequate data about the relation between unexplained syncope as the predictor of SCD ❑ ICD implantation indicated only in patients with recent history of more than one episode of syncope suspected to be ventricular tachyarrhythmia

Arrhythmogenic right ventricular cardiomyopathy : (Class I , Level of Evidence B)

❑ ICD implantation indicated in the setting of sustain VT leading syncope

Cardiac sarcoidosis : (Class I , Level of Evidence B)

❑ ICD implantation indicated in the presence of syncope due to ventricular tachycardia ❑ Mechanism of [[ventricular tachycardia] is macroreentry around granulomas and triggered activity and automaticity due to myocardial inflammation ❑ Inadequate data about The role of immunosuppression therapy in decreasing ventricular arrhythmia ❑ Immunosuppression therapy, permanent pacemaker in irreversible cases is recommended in AV block

Brugada : (Class IIa, Level of Evidence B)

❑ ICD implantation in suspected arrhythmia leading syncope

Brugada : (Class IIb, Level of Evidence B)

❑ EPS may be helpful for finding ventricular arrhythmia leading syncope

Brugada : (Class III, Level of Evidence B)

❑ ICD is not recommended in patients suspected reflex mediated syncope

Short QT syndrome : (Class IIb, Level of Evidence C)

❑ ICD implantation in the presence of documented ventricular arrhythmia and family history of SCD Short QT syndrome definition: QTc interval≤340 ms Syncope is not the risk factor of SCD in the absent of documented VT or VF

Long QT syndrome : (Class I, Level of Evidence B)

❑ Beta-blocker therapy in patients with frequent episodes of syncope reduces risk of fatal arrhythmia specially in LQTS1 Long QT syndrome definition: QTc interval ≥ 500 ms

Long QT syndrome : (Class IIa, Level of Evidence B)

❑ICD implantation in syncope related arrhythmia in patients are on betablocker or intolerant to betablocker ❑ Left cardiac sympathectomy in frequent episodes of syncope arrhythmia in patients are on betablocker or intolerant to betablocker (LOR=C)

CPVT : (Class I, Level of Evidence C)

❑ Exercise restriction in patients suspected arrhythmia leading syncope ❑ Betablocker therapy for reduction of sympathetic activity in stress-induced tachyarrhythmia CPVT definition: catecholamine-induced (often exertional) bidirectional VT or polymorphic VT in the setting of a structurally normal heart and normal resting ECG

CPVT : (Class IIa, Level of Evidence C)

❑ Flecainide in patients with arrhythmia leading syncope in spite of betablocker therapy ❑ICD implantation in patients with arrhythmia leading syncope in spite of optimal medical therapy ([[LOR=B)

CPVT : (Class IIb, Level of Evidence C)

❑ Verapamil in patients with arrhythmia leading syncope during exercise in spite of betablocker therapy

Urgent Treatment

Recommended treatment is to allow the person to lie on the ground with his or her legs slightly elevated. As the dizziness and the momentary blindness passes, the person may experience visual disturbances in the form of small bright dots (phosphene). These will also pass within a few minutes. After initial stabilization, the treatment of syncope depends on the causes.

Cardiac Syncope

• Arrhythmia: For patient whose syncope is caused by bradycardia or heart block, a pacemaker may be considered to solve the problems. An implantable cardioverter defibrillator (ICD) may help the patient with repeated ventricular tachycardia. Sometimes, antiarrhythmic drugs may be helpful for some patients. These treatments should be ordered by the cardiologists.

Neurologic Syncope

• Medications: Medications, such as aspirin, warfarin or heparin.

Vasovagal Syncope

• Educating patients not to wear tight collars, not to cough with difficulty, and to try to urinate while sitting down instead of standing up.

Orthostatic Hypotension

• The patient should be careful when changing positions from sitting to standing.